Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

South Korea to secure coronavirus vaccines for 60% of population

09/14/2020 | 11:18pm EST

SEOUL, Sept 15 (Reuters) - South Korea said on Tuesday it plans to spend $146 million to procure coronavirus vaccines, initially aiming to secure a supply for 30 million people, or 60% of its population, as it battles persistent outbreaks of new cases.

The population target is higher than a World Health Organization (WHO) goal for the early purchase of supplies for 20% of the world's most vulnerable people, and at least 40% agreed by European Union nations, Britain and EU partners for their populations.

While South Korean authorities would like to inoculate the entire population of 52 million, uncertainty around any vaccine's safety, efficacy and development was limiting investment, Prime Minister Chung Sye-kyun told a cabinet meeting.

Global vaccine makers are racing to develop an effective vaccine against the virus that has killed more than 925,000 people since it emerged in China late last year.

Chung said the government would negotiate with relevant international organisations and vaccine makers to secure the supply and would buy more as developments unfolded.

In August, South Korea said it planned to join the COVAX facility, a global novel coronavirus vaccine allocation plan co-led by the WHO, which aims to help buy and fairly distribute the shots.

South Korea will buy 20 million doses of vaccine from the COVAX scheme, enough for 10 million people, and 40 million doses from private drug-makers, health authorities said in a statement.

The government has prepared 172 billion won ($146 million) to pay for vaccines, including $70 million for the 20 million doses from the COVAX facility.

South Korea has been one of the world’s coronavirus mitigation success stories, with an aggressive testing and tracing strategy, but it has nevertheless been battling persistent spikes in infections.

It reported 106 new coronavirus cases as of Monday, taking total infections to 22,391 with 367 deaths.

SK Bioscience in July agreed to manufacture AstraZeneca’s experimental vaccine, which has shown promise, and signed a deal with Novavax Inc last month to produce a component of the U.S. drug developer's experimental coronavirus vaccine. ($1 = 1,179.8300 won) (Reporting by Sangmi Cha; Editing by Ana Nicolaci da Costa, Robert Birsel)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.78% 7722 Delayed Quote.4.62%
NOVAVAX, INC. 0.45% 128 Delayed Quote.14.28%
SK CHEMICALS CO.,LTD. 4.26% 392000 End-of-day quote.-0.13%
All news about ASTRAZENECA PLC
01:57pPeru says Sinopharm, Pfizer seek approval for their COVID-19 vaccines
01:43pASTRAZENECA : India to start COVID vaccine exports on Wednesday
01:37pASTRAZENECA : India to start COVID vaccine exports on Wednesday
11:35aBrussels targets vaccinating at least 70% of EU adults by summer
07:45aASTRAZENECA : India's homegrown vaccine developer warns some to avoid shot
07:31aJapan has pre-ordered COVID-19 vaccine doses for more than four times its pop..
06:44aSputnik-AstraZeneca vaccine trials to start in February, says R-Pharm
06:38aPhilippines to buy 20 million Moderna vaccine doses as COVID-19 cases rise
05:00aASTRAZENECA : Thailand defends royal company's role in vaccine strategy
04:39aASTRAZENECA : Thailand defends royal company's role in vaccine strategy
More news
Financials (USD)
Sales 2020 26 399 M - -
Net income 2020 2 970 M - -
Net Debt 2020 13 223 M - -
P/E ratio 2020 30,3x
Yield 2020 3,65%
Capitalization 101 B 137 B -
EV / Sales 2020 4,31x
EV / Sales 2021 3,72x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 126,16 $
Last Close Price 77,22 $
Spread / Highest target 102%
Spread / Average Target 63,4%
Spread / Lowest Target 8,90%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG1.93%303 276
NOVARTIS AG1.65%217 178
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993